Remdesivir

Remdesivir is a broad-spectrum antiviral developed by Gilead Sciences. Remdesivir is a prodrug, and upon entry into cells, it is metabolized into the nuceotide triphosphate GS-441524.
Remdesivir was investigated for activity for Ebola virus, but it was found to have activity against the coronavirus (CoV) family of viruses including severe acute repiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV), and in vitro activity against SARS-CoV2.

Please contact us at for specific academic pricing.

Background

Remdesivir is a prodrug that is converted in vivo into GS-441524 monophosphate, a ribonucleotide analog, via actions of esterases and phosphoramidase. This in turn is futher phosphorylated to it active metabolite triphosphate by nucleoside-phosphate kinases. The active metabolite of Remdesivir interferes with the action of viral RNA-dependent RNA polymerase and evades proofreading by viral exoribonuclease (ExoN), causing a decrease in viral RNA production. For the RNA-Dependent RNA Polymerase of MERS-CoV, SARS-CoV-1, and SARS-CoV-2 arrest of RNA synthesis occurs after incorporation of three additional nucleotide, thus Remdesivir is classified as a delayed chain terminator.
Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro.